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(1 .2) .as well as several previously reported prospective drug "add-on"
trials (3-6) . provide very strong evidence of digoxin's clinical efficacy .
The issue of digoixin's e&ct on survival must, as we pointed out in our
article, be addressed (its is currently underway) to complete the drug's
clinical profile,
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Synchronized Coronary Venous Retroperfusion
We would like to comment on the recently published report by
Boekstegers et al . (1) . We as scientists who have used the technique
of synchronized coronary venous retroperfusion extensively, both
experimentally and clinically, would like to caution the readers with
regard to certain issues before they extrapolate these data clinically .
Our concerns regard safety, feasibility and efficacy .
With respect to safety, it has been - ;town in several studies (2-4)
that retroperfusion coronary venous pressures <40 mm Hg (mean
pressure) and 60 mm Hg (peak pressure) were safe . The manufac-
turer also limits mean pressures at 40 min Hg (5) . In this study
during retroperfusionlretroi nfus ion, the coronary venous pressures
were as high as 89 ± 24 mm Hg for peak pressure and 61 ±
16 mm Hg for mean pressure (I [Table 31) . In a previous publication,
Boekstegers et al . (6) state that pressures >50 mm Hg are dangerous
and lead to myocardial hemorrhage and edema. The authors did not
observe any detrimental effects from these high pressures ; however,
the duration of pumping support retruperfusion in these studies was
limited to 10 min . On the basis of previous clinical studies, and to
ensure safely of the synchronized retroperfusion technique, the
pump is actually equipped with a cutoff switch that shuts off the
pump when unacceptably high pressures develop within the coro-
nary veins (5) . Also of note is that the rest pressures in the animal
before the start of retroperfusion were high at -20 mm Hg,
indicating probable venous occlusion by the balloon-tipped 8 .5F
synchronized retroperfusion catheter, thus hampering venous drain-
age. Previous safety studies (2-4) demonstrate the importance of
normal rest coronary venous pressure, which must equal right atrial
pressure to ensure adequate venous drainage .
The feasibility of the synchronized retroperfusion technique
encompassed the rapidity with which the
technique
can be set dp
and the catheter insertion time . Retroperfusion has been effective
when the catheter is placed in the great cardiac vein . Selective
cannulation of the anterior interventricular vein is not necessary .
The authors suggest greater efficacy if the anterior interventricular
vein is cannulated, which will make the technique more time-
consuming and protection restricted to left anterior descending
coronary artery territory . Retroperfusion is dependent or, arterio-
venous gradients; hence the retroperfusate will go toward the
ischemic areas (low pressure) even without selective cannulation of
the draining veins (7) .
Boekstegers et al . (1) used intra myocardial oxygen tension and
regional myocardial function using ultrasound crystals as end
points . The efficacy with suction and retroinfusion did reach statis-
tical significance . but we are unsure whether the degree of improve-
ment is clinically relevant . The authors used a 10-min ischemia
followed by a 50-min reperfusion model . This does not simulate a
percutaneous Iransluminal coronary angioplasty model adequately,
where there are repeated episodes of short ischemia . The 50-min
reperfusion eficr 10-min occlusion was too short to cause myocar-
dial necrosis or simulate an acute myocardial infarction . The study
thus has limited clinical applicability .
The technique of synchronized coronary venous retroperfusion
when applied property and according to the instructions of the
manufacturer (Relroperfusion Systems, Inc . !5)) has been shown to
be safe, feasible and effective in numerous clinical trials (8-11 . Me
manufacturer has recently been issued a letter of approval from the
U .S. Food and Drug Administration on the basis of the safely
guidelines and effectiveness of the technique . As scientists involved
in the original experimental and clinical studies, we have great
concern with regard to applicability of this technique by Boekste-
gers et al . (I) .
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Re*
Kar et al . raise three issues witi regard to our recent report (1) . The
first is the safety of peak and mean coronary venous pressures
during retroperfusion . The definition of "mean" coronary venous
pressure must be clarified because previous studies (2-5) did not
differentiate between mean diastolic or systolic pressures . With
regard to the data from our article, mean coronary venous pressure
was not 61 mm Hg, as stated by Kar et al ., but 50 mm Hg in the
animals treated by synchronized retroperfusion, and it was only
34 mm Hg in the animals treated by selective suction and retroin-
fusion. Furthermore, obstructipn of the great cardiac vein by
the
S,5F retrroperfilsion catheter was excluded by previous determina-
tion of the rest pressures using a 3F catheter . In a previous report
(6), we stated that 50 mm Hg was the suggested limit of coronary
venous peak pressure by others
(2-4) . In these studies the suggested
safety limits for long-term application (several hours) were derived
from the experience of studies without adequate coronary venous
drainage (7,8)
but were not actually caused by inducing damage
related to certain coronary venous pressures, Hence, the observa-
tion that using a limit of 50 or 60 mm Hg for peak or 40 mm Hg for
mean coronary venous
pressures was safe in experimental (2-4,6)
and clinical studies (5,9-t0) does not necessarily imply that higher
pressures are harmful, in particular with regard
to short•term
(sever minutes) application of retroinfusion, as demonstrated
in
our study
. Furthermore, differences with regard to coronary venous
wall stress may occur if pressure is reduced to zero intermittently by
active suction during selective suction and retroinfusion compared
with synchronized retroperfusion
. Therefore, definitive upper safety
limits for peak and mean coronary venous pressures in short- and
long-term applications of coronary venous retroinfusion--in our
opinion--are not yet clear, as stated by Kar et al
.
The second issue is the feasibility of the selective suction and
retroinfusion technique
. It has been shown by several studies that
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the main difficulty using retroinfusion techniques was to enter the
coronary sinus but not to advance into the great cardiac vein
(5,9,10)
. Therefore, we don't believe that the selective suction and
retroinfusion technique will be snore tithe-consuming than synchro-
nized retroperfusion, which is also supported by the fact that smaller
catheter sizes used for selective suction and retroinfusion should
make it easier to advance it into the smaller veins
.
The third issue is the clinical efficacy of selective suction and
retroinfusion and synchronized retroperfusion . Because our study
was preclinicat, we did not intend to anticipate any clinical conclu-
sion
. Our experimental results, however, suggest that selective
suction and retroinfusion may indeed be more effective than syn-
chronized retroperfusion in pigs. The finding of clearly superior
preservation of regional myocardial function by selective suction
and retroinfusion compared with synchronized retroperfusion (71%
vs. 7% of baseline value) during the first minute of arterial occlusion
suggests the clinical relevance of myocardial protection by selective
suction and retroinfusion for application during short-term repeated
percutaneous transluminal coronary angioplasty as well . Myocardial
oxygen tension and regional myocardial function appeared to be
more relevant variables for comparing the efficacy of selective
suction and retroinfusion and synchronized retroperfusion in an
experimental model of coronary angioplasty than the development
of myocardial necrosis . Furthermore, we did not simulate myocar-
dial infarction in ibis study because the efficacy of selective suction
and retroinfusion in reducing myocardial necrosis has been demon-
strated previously (6) .
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